{
  "ticker": "CLLS",
  "company_name": "Cellectis S.A.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04106076",
      "title": "Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukaemia",
      "start_date": "2019-07-11",
      "completion_date": "2019-12-05",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    },
    {
      "nct_id": "NCT04150497",
      "title": "Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Acute Lymphoblastic Leukemia",
      "start_date": "2019-10-14",
      "completion_date": "2026-06-30",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    },
    {
      "nct_id": "NCT03203369",
      "title": "Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
      "start_date": "2017-06-28",
      "completion_date": "2019-06-27",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    },
    {
      "nct_id": "NCT04142619",
      "title": "Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory Multiple Myeloma",
      "start_date": "2019-11-21",
      "completion_date": "2023-06-18",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    },
    {
      "nct_id": "NCT05607420",
      "title": "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "start_date": "2022-11-01",
      "completion_date": "2027-08",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    },
    {
      "nct_id": "NCT03190278",
      "title": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Relapsed/Refractory Acute Myeloid Leukemia",
      "start_date": "2017-06-19",
      "completion_date": "2025-12",
      "enrollment": 0,
      "sponsor": "Cellectis S.A."
    }
  ],
  "summary": {
    "total_trials": 6,
    "by_phase": {
      "PHASE1": 4,
      "PHASE1, PHASE2": 2
    },
    "by_status": {
      "WITHDRAWN": 1,
      "RECRUITING": 2,
      "TERMINATED": 2,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 3,
    "completed_trials": 0,
    "conditions": [
      "Acute Myeloid Leukaemia",
      "B-cell Acute Lymphoblastic Leukemia",
      "B-cell Non-Hodgkin Lymphoma (B-NHL)",
      "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",
      "Relapsed/Refractory Acute Myeloid Leukemia",
      "Relapsed/Refractory Multiple Myeloma"
    ],
    "lead_stage": "phase_1"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:30.626996",
    "search_query": "Cellectis S.A.",
    "url": "https://clinicaltrials.gov/search?term=Cellectis+S.A."
  }
}